1132819-16-9
1132819-16-9
Chemical Structure
Oxaliplatin-d10
- CAS No.: 1132819-16-9
- Formula:C8H4D10N2O4Pt
- Molecular Weight:407.35
InChIKey: ZROHGHOFXNOHSO-YYKMXZQESA-L
SMILES: O=C1[O-][Pt+2]2([O-]C1=O)[NH2][C@@]3([2H])[C@](C([2H])([2H])C([2H])([2H])C([2H])([2H])C3([2H])[2H])([2H])[NH2]2
Biological Activity: Oxaliplatin-d10 is a deuterium labeled Oxaliplatin (HY-17371). Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oxaliplatin-d10 | Oxaliplatin-d10 is a deuterium labeled Oxaliplatin (HY-17371). Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaliplatin (Standard) | 99.99% | Oxaliplatin (Standard) is the analytical standard of Oxaliplatin. This product is intended for research and analytical applications. Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxaliplatin | 99.65% | Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief]
- [2]. Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347. [Content Brief]
- [3]. Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40. [Content Brief]
